FY2018 Earnings Estimate for Shire PLC (SHPG) Issued By SunTrust Banks
Shire PLC (NASDAQ:SHPG) – Research analysts at SunTrust Banks dropped their FY2018 earnings per share (EPS) estimates for shares of Shire PLC in a report issued on Tuesday. SunTrust Banks analyst J. Boris now expects that the brokerage will earn $18.74 per share for the year, down from their previous forecast of $18.78. SunTrust Banks also issued estimates for Shire PLC’s FY2019 earnings at $23.72 EPS.
Other research analysts also recently issued research reports about the company. Piper Jaffray Cos. set a $201.00 price objective on Shire PLC and gave the stock a “hold” rating in a report on Saturday, October 1st. Leerink Swann restated a “buy” rating on shares of Shire PLC in a report on Saturday, October 1st. Jefferies Group restated a “buy” rating on shares of Shire PLC in a report on Friday, July 1st. Sanford C. Bernstein restated an “outperform” rating and set a $222.00 price target on shares of Shire PLC in a report on Thursday, June 9th. Finally, Royal Bank Of Canada restated an “outperform” rating on shares of Shire PLC in a report on Wednesday, June 15th. Five analysts have rated the stock with a hold rating and twenty-two have assigned a buy rating to the stock. Shire PLC currently has a consensus rating of “Buy” and an average target price of $232.75.
Shares of Shire PLC (NASDAQ:SHPG) traded up 0.21% during mid-day trading on Friday, hitting $193.95. The stock had a trading volume of 466,580 shares. The firm has a market cap of $57.77 billion, a PE ratio of 40.31 and a beta of 1.16. The stock’s 50-day moving average price is $195.68 and its 200-day moving average price is $186.83. Shire PLC has a 52-week low of $147.60 and a 52-week high of $231.32.
Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 EPS for the quarter, topping the consensus estimate of $3.03 by $0.35. The firm earned $2.43 million during the quarter, compared to the consensus estimate of $2.28 billion. Shire PLC had a return on equity of 17.70% and a net margin of 13.19%. The company’s quarterly revenue was up 55.9% compared to the same quarter last year. During the same period in the prior year, the business posted $2.63 earnings per share.
Institutional investors have recently added to or reduced their stakes in the stock. Macquarie Group Ltd. purchased a new position in Shire PLC during the second quarter valued at $5,561,000. Northwestern Mutual Wealth Management Co. boosted its position in Shire PLC by 157.9% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 8,645 shares of the biopharmaceutical company’s stock valued at $1,591,000 after buying an additional 5,293 shares during the last quarter. Cowen Group Inc. purchased a new position in Shire PLC during the second quarter valued at $920,000. Beacon Trust Co. purchased a new position in Shire PLC during the second quarter valued at $2,643,000. Finally, IFP Advisors Inc boosted its position in Shire PLC by 871.9% in the second quarter. IFP Advisors Inc now owns 2,702 shares of the biopharmaceutical company’s stock valued at $497,000 after buying an additional 2,424 shares during the last quarter. 24.26% of the stock is currently owned by hedge funds and other institutional investors.
The company also recently declared a dividend, which will be paid on Friday, October 7th. Stockholders of record on Friday, September 9th will be issued a dividend of $0.139 per share. The ex-dividend date of this dividend is Wednesday, September 7th. Shire PLC’s payout ratio is 15.63%.
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.